Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population

Purpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®). Study design: Non-randomized prospective observational case study. Methods: Five eyes of 5 patients with naïve CNV secondary to pathological...

Full description

Bibliographic Details
Main Authors: Hernan Andres Rios, Anne Brieke, Shirley Rosenstiehl, Francisco Rodriguez
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:The Pan-American Journal of Ophthalmology
Subjects:
Online Access:http://www.thepajo.org/article.asp?issn=2666-4909;year=2017;volume=16;issue=2;spage=43;epage=45;aulast=Rios;type=0
_version_ 1818613234249236480
author Hernan Andres Rios
Anne Brieke
Shirley Rosenstiehl
Francisco Rodriguez
author_facet Hernan Andres Rios
Anne Brieke
Shirley Rosenstiehl
Francisco Rodriguez
author_sort Hernan Andres Rios
collection DOAJ
description Purpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®). Study design: Non-randomized prospective observational case study. Methods: Five eyes of 5 patients with naïve CNV secondary to pathological myopia were recruited for this study. Demographics, basal best-corrected visual acuity, grade of myopia, angiographic and tomographic features were obtained at baseline. A loading dose of three monthly Ranibizumab (Lucentis®) injections were given to the recruited subjects. After completion of the loading dose, a complete ophthalmological evaluation, angiography and spectral domain optical coherence tomography (SD-OCT) were obtained subsequently at six and twelve months of follow-up. Results: The mean age of patients was 45 years. The mean spherical equivalent refractive error was -13.85. At baseline, the mean number of letters was 61.4 and at follow-up to 12 months the mean number of letters was 73.2. The central foveal thickness and subfoveal choroidal thickness decreased in all cases. After loading dose there was no persistent nor recurrent leakage from treated CNV on fluorescein angiography. FAF evidenced an increase in the area of atrophy, with a special circle pattern around the CNV. Conclusions: This study showed a functional and morphologic improvement at 12 months in five Colombian subjects treated with a loading dose of 3 Ranibizumab monthly injections.
first_indexed 2024-12-16T15:58:52Z
format Article
id doaj.art-2b86869d10974a928bc6ce13b7b752a5
institution Directory Open Access Journal
issn 2666-4909
2666-4909
language English
last_indexed 2024-12-16T15:58:52Z
publishDate 2017-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series The Pan-American Journal of Ophthalmology
spelling doaj.art-2b86869d10974a928bc6ce13b7b752a52022-12-21T22:25:30ZengWolters Kluwer Medknow PublicationsThe Pan-American Journal of Ophthalmology2666-49092666-49092017-01-011624345Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian PopulationHernan Andres RiosAnne BriekeShirley RosenstiehlFrancisco RodriguezPurpose: To describe the characteristics of myopic choroidal neovascular membranes of hispanic subjects treated with a loading dose of Ranibizumab (Lucentis®). Study design: Non-randomized prospective observational case study. Methods: Five eyes of 5 patients with naïve CNV secondary to pathological myopia were recruited for this study. Demographics, basal best-corrected visual acuity, grade of myopia, angiographic and tomographic features were obtained at baseline. A loading dose of three monthly Ranibizumab (Lucentis®) injections were given to the recruited subjects. After completion of the loading dose, a complete ophthalmological evaluation, angiography and spectral domain optical coherence tomography (SD-OCT) were obtained subsequently at six and twelve months of follow-up. Results: The mean age of patients was 45 years. The mean spherical equivalent refractive error was -13.85. At baseline, the mean number of letters was 61.4 and at follow-up to 12 months the mean number of letters was 73.2. The central foveal thickness and subfoveal choroidal thickness decreased in all cases. After loading dose there was no persistent nor recurrent leakage from treated CNV on fluorescein angiography. FAF evidenced an increase in the area of atrophy, with a special circle pattern around the CNV. Conclusions: This study showed a functional and morphologic improvement at 12 months in five Colombian subjects treated with a loading dose of 3 Ranibizumab monthly injections.http://www.thepajo.org/article.asp?issn=2666-4909;year=2017;volume=16;issue=2;spage=43;epage=45;aulast=Rios;type=0myopic choroidal neovascular membraneranibizumabhispanic population.
spellingShingle Hernan Andres Rios
Anne Brieke
Shirley Rosenstiehl
Francisco Rodriguez
Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
The Pan-American Journal of Ophthalmology
myopic choroidal neovascular membrane
ranibizumab
hispanic population.
title Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
title_full Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
title_fullStr Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
title_full_unstemmed Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
title_short Myopic Choroidal Neovascularization Membranes Treated With Ranibizumab in Colombian Population
title_sort myopic choroidal neovascularization membranes treated with ranibizumab in colombian population
topic myopic choroidal neovascular membrane
ranibizumab
hispanic population.
url http://www.thepajo.org/article.asp?issn=2666-4909;year=2017;volume=16;issue=2;spage=43;epage=45;aulast=Rios;type=0
work_keys_str_mv AT hernanandresrios myopicchoroidalneovascularizationmembranestreatedwithranibizumabincolombianpopulation
AT annebrieke myopicchoroidalneovascularizationmembranestreatedwithranibizumabincolombianpopulation
AT shirleyrosenstiehl myopicchoroidalneovascularizationmembranestreatedwithranibizumabincolombianpopulation
AT franciscorodriguez myopicchoroidalneovascularizationmembranestreatedwithranibizumabincolombianpopulation